# Prolynx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prolynx

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.prolynxinc.com/
- Total disclosed funding: $70M
- Latest round: Series A (Dec 11, 2025)
- Investors on record: 3

## About

Prolynx is a US-based company specializing in the development of innovative drug delivery systems focused on obesity and metabolic diseases, utilizing proprietary technology for extended dosing regimens.Founded in 2009 and headquartered in San Francisco, US, Prolynx develops therapeutic candidates aimed at addressing obesity and metabolic disorders. The company has engaged in one significant funding round, raising USD 70.00 mn through a Series A round in December 2025, with key investments from 5AM Ventures, Monograph Capital Partners, and OrbiMed Advisors.Prolynx is focused on developing a portfolio of ultra-long-acting therapeutic candidates aimed at addressing obesity and related metabolic diseases. Their core products leverage proprietary half-life extension technology, allowing for once-monthly and once-quarterly dosing regimens. This technology enhances treatment consistency, improves tolerability, and optimizes pharmacokinetics, ultimately aiming to provide patients with a more manageable approach to long-term weight management and metabolic health. Prolynx targets a diverse client base, including healthcare providers and institutions that treat obesity and metabolic disorders, with products designed for markets in North America and Europe, where the prevalence of these health issues is particularly high.Prolynx's revenue model is structured around strategic partnerships and potential collaborations with healthcare providers and pharmaceutical distributors. The company is expected to generate revenue through the sale of its ultra-long-acting medicines, marketed directly to healthcare institutions and clinics specializing in obesity and metabolic disease treatment. Transactions will involve agreements with healthcare providers to supply these products, potentially incorporating subscription models for ongoing treatment regimens. While specific pricing plans and flagship products are not disclosed, the framework suggests that pricing may align with industry standards for therapeutics, reflecting the added value of extended dosing intervals and enhanced patient outcomes.In December 2025, Prolynx raised USD 70.00 mn in Series A funding to advance its pipeline of long-acting therapies toward clinical proof-of-concept. The company plans to leverage this funding to accelerate the development of new therapeutic candidates designed for the obesity and metabolic disease markets. Additionally, Prolynx aims to expand its presence in North America and Europe, targeting healthcare providers that specialize in these conditions.

## Funding rounds

- Series A, Dec 11, 2025, $70M — OrbiMed Advisors, 5AM Ventures, Monograph Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A